Rhythm Pharmaceuticals reported its second-quarter 2026 financial results alongside a business update that focused heavily on the early U.S. rollout of IMCIVREE (setmelanotide) for acquired hypothalamic obesity, or HO. According to the company, the launch has opened with strong initial activity following FDA approval.
A key figure in the update was more than 400 patient start forms submitted as of June 30, 2026. That metric is often watched as an early sign of commercial uptake because it can reflect prescriber interest and the first steps toward treatment access.
The company also said global sales of IMCIVREE contributed net product revenue in the second quarter, underscoring the drug's role as the center of Rhythm's commercial business. While the release highlighted financial performance, the HO launch appeared to be one of the main operational developments for the period.
For investors and healthcare market watchers, the next question will be how quickly those early patient starts translate into broader use in the U.S. market. The quarter positions Rhythm Pharmaceuticals at an important point, balancing financial execution with the expansion of IMCIVREE into acquired hypothalamic obesity.
